Multi-parametric Ultrasound in the Diagnosis of Prostate Cancer Webcast (2017)

Member only benefit! Transrectal ultrasound is critical to biopsy guidance for the diagnosis of prostate cancer. However, ultrasound has the ability to improve diagnostic accuracy and may perform as well as multi-parametric MRI in identifying suspicious lesions. This course will familiarize participants with gray-scale ultrasound, color and power Doppler ultrasound, elastography and contrast-enhanced ultrasound as modalities which alone or in combination may improve the diagnosis of prostate cancer.
 
This activity satisfies the AIUM requirement - "The physician should complete 10 hours of AMA PRA Category 1 Credits™ specific to genitourinary ultrasound every 3 years."
 

Learning Objectives

After attending this course, participants will be able to:

  1. Employ the physics behind each of the four modalities of multi-parametric ultrasound.
  2. Identify the potential advantages and limitations of each of the four modalities of multi-parametric ultrasound.
  3. Deploy the technology to improve the diagnosis of prostate cancer in appropriately selected populations of patients.
  4. Outline the additional resources and expertise necessary to use the four modalities of multi-parametric ultrasound.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
07/17/2017
Course expires: 
07/17/2020
Rating: 
0

Faculty Disclosures
Course Director:

  • Pat Fulgham, MD: Urology Clinics of North Texas: Investment Interest

Faculty:

  • Edouard Trabulsi, MD, FACS: GenomeDx: Consultant or Advisor
  • Tillmann Loch, MD, PhD: DGU: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development ; EAU: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; Astellas PharmaGmbH: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; Glaxosmithkline IHCLimited: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; ANNA Technologies GmbH: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; CHINESE MEDICAL SSOCIATION: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; Spr: Leadership Position, Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Owner, Product Development; DGU: Other; EAU: Other; AUA: Other; WJU: Other

 
Planner Disclosures
Education Council

  • Timothy Charles Brand, M.D.: Nothing to disclose
  • Anthony A. Caldamone MD: Nothing to disclose
  • Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
  • Sam S. Chang, MD: astellas: Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor; tolmar: Consultant or Advisor
  • Matthew S. Christman MD: Nothing to disclose
  • Jody Donaldson (AUA Staff): Nothing to disclose
  • Shelby Englert (AUA Staff): Nothing to disclose
  • Matthew Thomas Gettman, MD: Nothing to disclose
  • Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
  • Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
  • William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
  • William C. Hulbert Jr. MD: Nothing to disclose
  • Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
  • Mark L. Jordan MD,FACS: Nothing to disclose
  • Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research; Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
  • Martin A. Koyle MD: Nothing to disclose
  • John Stephen Lam MD: Nothing to disclose
  • Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial: Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
  • Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
  • Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
  • Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
  • Christopher Porter, MD: Nothing to disclose
  • Gail S. Prins PhD: Nothing to disclose
  • Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
  • Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Scientific Study or Trial
  • Lee Richstone, MD: Nothing to disclose
  • Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
  • Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
  • Joseph A. Smith Jr.,MD: Nothing to disclose
  • Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
  • Edouard John Trabulsi, MD: Nothing to disclose
     

Urologic Diagnostic and Therapeutic Imaging Committee

  • Ronney Abaza ,MD: Intuitive Surgical Inc: Other; Surgiquest Inc.: Scientific Study or Trial; Ohio Urological Society: Leadership Position
  • Dean George Assimos MD: Med Review in Urology: Health Publishing; Urology Times: Health Publishing; National Institute of Health (NIH): Scientific Study or Trial
  • Mark S. Austenfeld MD: ABU: Leadership Position             
  • Marc A Bjurlin, DO:  Nothing to disclose
  • David Y. T. Chen: Pfizer, Inc: Investment Interest; Pfizer, Inc: Investment Interest; Argos Therapeutic: Consultant or Advisor
  • John Warren Davis, MD: Genprobe: Scientific Study or Trial;          Janssen: Scientific Study or Trial; : Myriad Genetics: Consultant or Advisor, Meeting Participant or Lecturer; GenomeDx: Scientific Study or Trial; Intuitive Surgical: Consultant or Advisor, Meeting Participant or Lecturer; Mimedx: Scientific Study or Trial; British Journal of Urology International: Health Publishing
  • Jody Donaldson: Nothing to disclose
  • Shelby Englert: Nothing to disclose
  • Christopher Michael Gonzalez, MD: Aurasense: Investment Interest;l Coloplast: Other; AMS: Other
  • Peter M. Knapp Jr.,MD: Strand Diagnostics LLC: Consultant or Advisor, Owner, Product Development; Animated Dynamics: Consultant or Advisor
  • Surena Fazeli Matin ,MD: Taris Biomedical LLC: Consultant or Advisor; UroGen: Consultant or Advisor
  • Timothy Dale McClure, MD: Nothing to disclose
  • Hao Gia Nguyen MD, PhD: Nothing to disclose
  • Christopher Porter, MD: Nothing to disclose
  • Alberto Javier Ramirez, MD: Nothing to disclose
  • Daniel B. Rukstalis, MD: Neotract, Inc: Meeting Participant or Lecturer, Scientific Study or Trial
  • Ajay Kumar Singla, MD: Nothing to disclose
  • MS. Stephanie Stinchcomb CPC: Nothing to disclose

Method of Participation
Estimated time to complete this activity: 2 hours
 
Release Date: July, 2017
Expiration Date: July, 2020
 
Accreditation Statement 
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
 
Other Learners 
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
 

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
  
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation

Accreditation Period

Course opens: 
07/17/2017
Course expires: 
07/17/2020
Please login or register to take this course.